-
-
-
-
-
-
-
RenovoRx, Inc. (RNXT) Misses Q1 EPS by 1c
-
-
-
-
-
-
-
RenovoRx, Inc. (RNXT) Reports In-Line Q3 EPS
-
-
-
-
-
-
-
RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights
-
-
-
-
-
-
-
RenovoRx (RNXT) Files New International Patent for Novel Targeted Combination Drug-Delivery Oncology Therapy Platform
-
-
-
-
-
-
-
RenovoRx Announces New Positive Interim Phase III Data Demonstrating RenovoGemâ„¢ Delays Cancer Progression by Eight Months in Locally Advanced Pancreatic Cancer
-
-
-
-
-
-
-
RenovoRx (RNXT) Reports Positive New Data from Phase III Clinical Trial Interim Analysis
-
-
-
-
-
-
-
RenovoRx Reports Second Quarter 2022 Financial Results
-
1,218,242 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

